Site-directed mutagenesis modified glycoprotein hormones and methods of use
US5635475A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | May 16, 1995 |
| Grant date | Jun 3, 1997 |
| Priority date | — |
| Expiry date | May 16, 2015 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Described are new glycoprotein hormones capable of competing with natural hormones for the normal receptor binding sites but substantially incapable of effecting post receptor activities. The glycoprotein hormones of the present invention have had specific (rather than all) oligosaccharide chains removed so as to effectively diminish biologic activity while not significantly reducing plasma half-life, thus improving the molecules effectiveness as an antagonist compared with conventionally-produced molecules. The preferred glycoprotein hormones are ideally obtained by site-directed mutagenesis to selectively deglycosylate the protein. Also described are therapeutic treatments comprising the administration of the recombinant glycoprotein hormones of the present invention as hormone antagonists.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.